Access Pharma (ACCP)is a biopharmaceutical company focused on developing a range of pharmaceuticals primarily based upon the company s three key drug delivery technologies. Access currently has one approved product MuGard for the management of oral mucositis. Two cancer drug candidates ProLindac and Thiarabine are in phase II studies.
We are especially impressed with the company s Cobalaminbased oral drug delivery system. Both oral insulin and human growth hormone have achieved unprecedented oral bioavailability in animal models. Current share price is undervalued. We encourage investors accumulate the company s shares. Our six to twelve-month price target is $8.
ACCESS PHARMA (ACCP): Free Stock Analysis Report
Zacks Investment Research
